Jacques Simard,

Q: What Schools Are Affiliated With Jacques Simard,

Jacques Simard, is affiliated with the following schools: University of Melbourne, University of Cambridge, Université Laval

Jacques Simard,'s AcademicInfluence.com Rankings

Jacques Simard,

Philosophy

#6596

World Rank

#9654

Historical Rank

Logic

#3740

World Rank

#4940

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Jacques Simard, Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jacques Simard,'s Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers (2017) (1644)
Large-scale genotyping identifies 41 new loci associated with breast cancer risk (2013) (1063)
Association analysis identifies 65 new breast cancer risk loci (2017) (922)
The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds (1996) (866)
A candidate prostate cancer susceptibility gene at chromosome 17p (2001) (568)
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes (2018) (559)
MicroRNA Related Polymorphisms and Breast Cancer Risk (2014) (557)
Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. (2003) (534)
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer (2013) (534)
Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer (2015) (502)
Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants (2015) (471)
Is dehydroepiandrosterone a hormone? (2005) (454)
Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) (2011) (447)
Molecular Biology of the 3-Hydroxysteroid Dehydrogenase/5-4 Isomerase Gene Family (2005) (442)
A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. (1995) (433)
Genome-wide association studies identify four ER negative–specific breast cancer risk loci (2013) (411)
The key role of 17β-hydroxysteroid dehydrogenases in sex steroid biology (1997) (411)
Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk (2013) (405)
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. (2015) (390)
RAD51B in Familial Breast Cancer (2016) (366)
BRCA2 germline mutations in male breast cancer cases and breast cancer families (1996) (363)
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population (2010) (357)
DHEA and the Intracrine Formation of Androgens and Estrogens in Peripheral Target Tissues: Its Role during Aging (1998) (350)
DHEA and Its Transformation into Androgens and Estrogens in Peripheral Target Tissues: Intracrinology (2001) (348)
Structure and Expression of a New Complementary DNA Encoding the almost Exclusive 3β-Hydroxysteroid Dehydrogenase/Δ5-Δ4-lsomerase in Human Adrenals and Gonads (1991) (345)
Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families (1994) (325)
BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors (2019) (325)
Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. (2020) (322)
Large-scale genomic analyses link reproductive ageing to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair (2015) (308)
17beta-hydroxysteroid dehydrogenase (HSD)/17-ketosteroid reductase (KSR) family; nomenclature and main characteristics of the 17HSD/KSR enzymes. (1999) (304)
Intracrinology: role of the family of 17 beta-hydroxysteroid dehydrogenases in human physiology and disease. (2000) (295)
Characterization of cDNAs for human estradiol 17 beta-dehydrogenase and assignment of the gene to chromosome 17: evidence of two mRNA species with distinct 5'-termini in human placenta. (1989) (282)
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. (2007) (276)
DHEA and Peripheral Androgen and Estrogen Formation: Intracrinology (1995) (270)
The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers (2016) (267)
Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues (1986) (249)
Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer (2017) (244)
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. (2008) (238)
The emergence of an ethical duty to disclose genetic research results: international perspectives (2006) (235)
Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. (2013) (225)
Molecular biology of the 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family. (2005) (217)
Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers (2017) (211)
Congenital adrenal hyperplasia due to point mutations in the type II 3β–hydroxysteroid dehydrogenase gene (1992) (209)
Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations (2018) (206)
Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent (2016) (205)
Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group. (2006) (199)
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. (2010) (196)
Structure of human type II 5 alpha-reductase gene. (1992) (192)
Identification of six new susceptibility loci for invasive epithelial ovarian cancer (2014) (176)
PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS (2016) (174)
Characterization of rat 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase cDNAs and differential tissue-specific expression of the corresponding mRNAs in steroidogenic and peripheral tissues. (1991) (174)
Structure of two in tandem human 17β-hydroxysteroid dehydrogenase genes (1990) (173)
Characterization of human 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase gene and its expression in mammalian cells. (1990) (171)
EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium (1999) (166)
Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. (2013) (163)
A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. (2005) (161)
Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. (2005) (154)
A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer (2018) (149)
Role of 17β-Hydroxysteroid Dehydrogenases in Sex Steroid Formation in Peripheral Intracrine Tissues (2000) (147)
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation (2018) (147)
Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. (2016) (146)
Reproductive and Hormonal Factors, and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers: Results from the International BRCA1/2 Carrier Cohort Study (2009) (143)
Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores (2017) (142)
(S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen. (1997) (139)
Structure, function and tissue-specific gene expression of 3β-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase enzymes in classical and peripheral intracrine steroidogenic tissues (1992) (139)
Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. (1996) (137)
p300/CBP is required for transcriptional induction by interleukin-4 and interacts with Stat6 (1999) (135)
The key role of 17 beta-hydroxysteroid dehydrogenases in sex steroid biology. (1997) (134)
Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators. (1998) (128)
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. (2009) (124)
Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170 (2016) (122)
Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk (2013) (120)
Personalized early detection and prevention of breast cancer: ENVISION consensus statement (2020) (117)
BRCA1 mutations in Ashkenazi Jewish women. (1995) (114)
Prostate cancer susceptibility genes: lessons learned and challenges posed. (2003) (112)
DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers (2014) (112)
Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation (2014) (112)
Regulation of progesterone-binding breast cyst protein GCDFP-24 secretion by estrogens and androgens in human breast cancer cells: a new marker of steroid action in breast cancer. (1990) (111)
Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses (2019) (110)
Science behind total androgen blockade: from gene to combination therapy. (1993) (109)
Down-regulation of estrogen receptors by androgens in the ZR-75-1 human breast cancer cell line. (1989) (109)
Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. (2013) (109)
New insight into the molecular basis of 3beta-hydroxysteroid dehydrogenase deficiency: identification of eight mutations in the HSD3B2 gene eleven patients from seven new families and comparison of the functional properties of twenty-five mutant enzymes. (1999) (108)
Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. (2015) (107)
MOLECULAR BASIS OF CONGENITAL ADRENAL HYPERPLASIA DUE TO 3β-HYDROXYSTEROID DEHYDROGENASE DEFICIENCY (1993) (105)
Regulation of pro-gonadotropin-releasing hormone gene expression by sex steroids in the brain of male and female rats. (1989) (104)
Stimulation of growth hormone release and synthesis by estrogens in rat anterior pituitary cells in culture. (1986) (102)
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (2011) (101)
Structure and tissue-specific expression of 3ß-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase genes in human and rat classical and peripheral steroidogenic tissues (1992) (97)
The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. The BRCA1 Exon 13 Duplication Screening Group. (2000) (96)
Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer (2016) (95)
Genetic discrimination and life insurance: a systematic review of the evidence (2013) (94)
Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first‐line therapy (1993) (93)
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers (2012) (92)
Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells. (1991) (90)
Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia. (1998) (90)
Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. (2015) (86)
BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families (2005) (86)
Structure and sexual dimorphic expression of a liver-specific rat 3 beta-hydroxysteroid dehydrogenase/isomerase. (1990) (84)
GATA factors and the nuclear receptors, steroidogenic factor 1/liver receptor homolog 1, are key mutual partners in the regulation of the human 3beta-hydroxysteroid dehydrogenase type 2 promoter. (2005) (82)
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. (2011) (82)
Structure and tissue-specific expression of a novel member of the rat 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase (3 beta-HSD) family. The exclusive 3 beta-HSD gene expression in the skin. (1993) (82)
Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. (2018) (80)
11 Structure, regulation and role of 3β-hydroxysteroid dehydrogenase, 17β-hydroxysteroid dehydrogenase and aromatase enzymes in the formation of sex steroids in classical and peripheral intracrine tissues (1994) (80)
Pathology of Breast andOvarian Cancers among BRCA 1 and BRCA 2 Mutation Carriers : Results from the Consortium of Investigators of Modi fi ers of BRCA 1 / 2 ( CIMBA ) (2011) (78)
The Tumor Suppressor PALB2: Inside Out. (2019) (77)
Characterization of the effects of the novel non‐steroidal antiestrogen EM‐800 on basal and estrogen‐induced proliferation of T‐47D, ZR‐75‐1 and MCF‐7 human breast cancer cells in vitro (1997) (77)
Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells. (1997) (76)
Incorporating Truncating Variants in PALB2, CHEK2 and ATM into the BOADICEA Breast Cancer Risk Model (2016) (76)
Widespread tissue distribution of steroid sulfatase, 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase (3 beta-HSD), 17 beta-HSD 5 alpha-reductase and aromatase activities in the rhesus monkey. (1994) (76)
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. (2016) (76)
Perspective: prostate cancer susceptibility genes. (2002) (75)
Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes (2019) (74)
Induction of 3β-Hydroxysteroid Dehydrogenase/Δ5-Δ4 Isomerase Type 1 Gene Transcription in Human Breast Cancer Cell Lines and in Normal Mammary Epithelial Cells by Interleukin-4 and Interleukin-13 (1999) (73)
Molecular cloning, cDNA structure and predicted amino acid sequence of bovine 3β‐hydroxy‐5‐ene steroid dehydrogenase/Δ5‐Δ4 isomerase (1989) (73)
Structure and expression of a new complementary DNA encoding the almost exclusive 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase in human adrenals and gonads. (1991) (70)
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer (2017) (70)
Molecular basis of human 3β-hydroxysteroid dehydrogenase deficiency (1995) (70)
Localization of 3β-Hydroxysteroid Dehydrogenase in Rat Brain as Studied by in Situ Hybridization (1994) (69)
Shared heritability and functional enrichment across six solid cancers (2018) (67)
Stimulation of apolipoprotein D secretion by steroids coincides with inhibition of cell proliferation in human LNCaP prostate cancer cells. (1991) (67)
Additive stimulatory action of glucocorticoids and androgens on basal and estrogen-repressed apolipoprotein-D messenger ribonucleic acid levels and secretion in human breast cancer cells. (1992) (65)
Genetic mapping of the breast-ovarian cancer syndrome to a small interval on chromosome 17q12-21: exclusion of candidate genes EDH17B2 and RARA. (1993) (65)
The human type II 17 beta-hydroxysteroid dehydrogenase gene encodes two alternatively spliced mRNA species. (1995) (64)
Inhibition of cell cycle kinetics and proliferation by the androgen 5 alpha-dihydrotestosterone and antiestrogen N,n-butyl-N-methyl-11-[16' alpha-chloro-3',17 beta-dihydroxy-estra-1',3',5'-(10')triene-7' alpha-yl] undecanamide in human breast cancer ZR-75-1 cells. (1991) (64)
Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation (2016) (63)
Molecular biology and genetics of the 3 beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family. (1996) (62)
Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and androstenedione in the rat ventral prostate. (1989) (62)
Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium (2014) (62)
Molecular biology and genetics of the 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase gene family (1996) (61)
Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers (2012) (60)
Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants (2020) (60)
Inhibitory effect of estrogens on GCDFP-15 mRNA levels and secretion in ZR-75-1 human breast cancer cells. (1989) (60)
No evidence of mutations in the genes for type I and type II 3 beta-hydroxysteroid dehydrogenase (3 beta HSD) in nonclassical 3 beta HSD deficiency. (1994) (60)
Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures. (2015) (59)
European polygenic risk score for prediction of breast cancer shows similar performance in Asian women (2020) (59)
Characterization of macaque 3β-hydroxy-5-ene steroid dehydrogenase/Δ5-Δ4 isomerase: structure and expression in steroidogenic and peripheral tissues in primate (1991) (59)
Androgen receptor-mediated stimulation of 17 beta-hydroxysteroid dehydrogenase activity by dihydrotestosterone and medroxyprogesterone acetate in ZR-75-1 human breast cancer cells. (1993) (59)
Congenital adrenal hyperplasia due to 3beta-hydroxysteroid dehydrogenase/Delta(5)-Delta(4) isomerase deficiency. (2002) (58)
Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus (2016) (58)
Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers (2014) (58)
Interleukin-4 and interleukin-13 inhibit estrogen-induced breast cancer cell proliferation and stimulate GCDFP-15 expression in human breast cancer cells (1996) (58)
Localization of 3β-Hydroxysteroid DehydrogenaseΔ5-Δ4-Isomerase in Rat Gonads and Adrenal Glands by Immunocytochemistry and in Situ Hybridization (1990) (56)
Factors associated with an individual's decision to withdraw from genetic testing for breast and ovarian cancer susceptibility: implications for counseling. (2007) (56)
Structure-function relationships of 3β-hydroxysteroid dehydrogenase: Contribution made by the molecular genetics of 3β-hydroxysteroid dehydrogenase deficiency (1997) (56)
Intracrinology: the basis for the rational design of endocrine therapy at all stages of prostate cancer. (1993) (56)
Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families (2005) (55)
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. (2011) (55)
Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers (2019) (55)
No Evidence of False Reassurance among Women with an Inconclusive BRCA1/2 Genetic Test Result (2005) (54)
Characterization of the structure-activity relationships of rat types I and II 3 beta-hydroxysteroid dehydrogenase/delta 5 -delta 4 isomerase by site-directed mutagenesis and expression in HeLa cells. (1991) (54)
Association of the Variants CASP8 D302H and CASP10 V410I with Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers (2010) (53)
Response of Symbiotic Endomycorrhizal Fungi to Estrogens and Antiestrogens (1997) (53)
Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation. (2007) (53)
No Evidence of BRCA1/2 genomic rearrangements in high-risk French-Canadian breast/ovarian cancer families. (2006) (53)
Detection and functional characterization of the novel missense mutation Y254D in type II 3 beta-hydroxysteroid dehydrogenase (3 beta HSD) gene of a female patient with nonsalt-losing 3 beta HSD deficiency. (1994) (53)
Ontogeny and subcellular localization of 3β-hydroxysteroid dehydrogenase (3β-HSD) in the human and rat adrenal, ovary and testis (1992) (53)
Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer (2019) (53)
Regulation of 3β-Hydroxysteroid Dehydrogenase/Δ5-Δ4 Isomerase Expression and Activity in the Hypophysectomized Rat Ovary: Interactions between the Stimulatory Effect of Human Chorionic Gonadotropin and the Luteolytic Effect of Prolactin* (1990) (53)
Atrial natriuretic factor does not affect basal, forskolin- and CRF-stimulated adenylate cyclase activity, cAMP formation or ACTH secretion, but does stimulate cGMP synthesis in anterior pituitary (1986) (53)
Molecular basis of congenital adrenal hyperplasia in two siblings with classical nonsalt-losing 3 beta-hydroxysteroid dehydrogenase deficiency. (1994) (52)
Induction of 3β-Hydroxysteroid Dehydrogenase/ Isomerase Type 1 Expression by Interleukin-4 in Human Normal Prostate Epithelial Cells, Immortalized Keratinocytes, Colon, and Cervix Cancer Cell Lines1. (1999) (52)
Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. (2015) (51)
Ovarian 3 beta-hydroxysteroid dehydrogenase and sulfated glycoprotein-2 gene expression are differentially regulated by the induction of ovulation, pseudopregnancy, and luteolysis in the immature rat. (1992) (51)
Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2 (2015) (50)
History of LHRH agonist and combination therapy in prostate cancer (1996) (50)
Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families (2006) (50)
Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast (2014) (49)
Mutation R96W in cytochrome P450c17 gene causes combined 17 alpha-hydroxylase/17-20-lyase deficiency in two French Canadian patients. (1996) (48)
Expression of liver-specific member of the 3 beta-hydroxysteroid dehydrogenase family, an isoform possessing an almost exclusive 3-ketosteroid reductase activity. (1992) (48)
Multihormonal control of pre-pro-somatostatin mRNA levels in the periventricular nucleus of the male and female rat hypothalamus. (1990) (47)
Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers (2012) (47)
Prediction of breast cancer risk based on common genetic variants in women of East Asian ancestry (2016) (47)
The emergence of an ethical duty to disclose genetic research results: international perspectives (2006) (47)
Localization of the endogenous benzodiazepine ligand octadecaneuropeptide in the rat testis. (1990) (46)
Genetic predisposition to ductal carcinoma in situ of the breast (2016) (46)
Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families (2008) (45)
A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. (2018) (45)
EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium (2001) (45)
Results of a genome‐wide linkage analysis in prostate cancer families ascertained through the ACTANE consortium (2003) (45)
Local and systemic reduction by topical finasteride or flutamide of hamster flank organ size and enzyme activity. (1995) (44)
Genome-wide association study of germline variants and breast cancer-specific mortality (2019) (44)
The 3β-Hydroxysteroid Dehydrogenase/Isomerase Gene Family: Lessons from Type II 3β-HSD Congenital Deficiency (1996) (44)
A novel A10E homozygous mutation in the HSD3B2 gene causing severe salt-wasting 3beta-hydroxysteroid dehydrogenase deficiency in 46,XX and 46,XY French-Canadians: evaluation of gonadal function after puberty. (2000) (43)
Full oestrogenic activity of C19-Δ 5 adrenal steroids in rat pituitary lactotrophs and somatotrophs (1988) (43)
Functional analysis of genetic variants in the high-risk breast cancer susceptibility gene PALB2 (2019) (43)
Androgens and breast cancer. (1992) (43)
Crucial role of cytokines in sex steroid formation in normal and tumoral tissues (2001) (42)
Effects of sex steroids on regulation of the levels of C1 peptide of rat prostatic steroid-binding protein mRNA evaluated by in-situ hybridization. (1988) (42)
Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. (2011) (42)
COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration (2013) (41)
Mutation analysis of the BRCA1 gene in 23 families with cases of cancer of the breast, ovary, and multiple other sites. (1996) (41)
Distribution of 17 beta-hydroxysteroid dehydrogenase gene expression and activity in rat and human tissues. (1992) (41)
New concepts on the androgen sensitivity of prostate cancer. (1987) (41)
Are ATM Mutations 7271T→G and IVS10-6T→G Really High-Risk Breast Cancer-Susceptibility Alleles? (2004) (41)
Inverse relationships between cell proliferation and basal or androgen-stimulated apolipoprotein D secretion in LNCaP human prostate cancer cells (1994) (41)
Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). (2020) (40)
A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium. (2014) (40)
Suggestive evidence for a site specific prostate cancer gene on chromosome 1p36 (2000) (40)
Interleukin‐6 inhibits the potent stimulatory action of androgens, glucocorticoids and interleukin‐1α on apolipoprotein D and GCDFP‐15 expression in human breast cancer cells (1995) (39)
Occurrence of cytochrome P450c17 mRNA and dehydroepiandrosterone biosynthesis in the rat gastrointestinal tract (1995) (39)
Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women (2016) (39)
Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. (2015) (39)
Detection of polymorphisms in the estradiol 17 beta-hydroxysteroid dehydrogenase II gene at the EDH17B2 locus on 17q11-q21. (1993) (38)
Dopaminergic regulation of pre-proNPY mRNA levels in the rat arcuate nucleus (1991) (38)
Personalized medicine and access to health care: potential for inequitable access? (2012) (38)
Fine‐scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer (2016) (38)
Generation of an integrated transcription map of the BRCA2 region on chromosome 13q12-q13. (1996) (38)
Electron microscopic autoradiographic localization of prolactin mRNA in rat pituitary. (1989) (38)
Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&I) (2021) (38)
Health Behaviors and Psychological Distress in Women Initiating BRCA1/2 Genetic Testing: Comparison with Control Population (2008) (37)
Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers (2015) (37)
AURKA F31I Polymorphism and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: A Consortium of Investigators of Modifiers of BRCA1/2 Study (2007) (37)
Life insurance: genomic stratification and risk classification (2013) (37)
Synergistic action of prolactin (PRL) and androgen on PRL-inducible protein gene expression in human breast cancer cells: a unique model for functional cooperation between signal transducer and activator of transcription-5 and androgen receptor. (2002) (37)
Potent stimulatory effect of interleukin‐1α on apolipoprotein D and gross cystic disease fluid protein‐15 expression in human breast‐cancer cells (1994) (36)
Detection of a novel mutation (stop 468) in exon 10 of the low-density lipoprotein receptor gene causing familial hypercholesterolemia among French Canadians. (1994) (36)
A global functional analysis of missense mutations reveals two major hotspots in the PALB2 tumor suppressor (2019) (36)
Regulation of growth hormone mRNA and pro-opiomelanocortin mRNA levels by cyclic AMP in rat anterior pituitary cells in culture. (1986) (36)
Inhibitory effect of androgen on estrogen-induced prolactin messenger ribonucleic acid accumulation in the male rat anterior pituitary gland. (1989) (36)
An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. (2016) (35)
Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers (2020) (35)
Nonsalt-losing male pseudohermaphroditism due to the novel homozygous N100S mutation in the type II 3 beta-hydroxysteroid dehydrogenase gene. (1995) (35)
Glucocorticoid regulation of proopiomelanocortin mRNA levels in rat arcuate nucleus (1990) (34)
Rapid modulation of ovarian 3β-hydroxysteroid dehydrogenase/Δ 5-Δ 4 isomerase gene expression by prolactin and human chorionic gonadotropin in the hypophysectomized rat (1994) (33)
Identification of three mutations in the low‐density lipoprotein receptor gene causing familial hypercholesterolemia among French Canadians (1998) (33)
Identification of New Genetic Susceptibility Loci for Breast Cancer Through Consideration of Gene‐Environment Interactions (2014) (33)
Inherited mutations in BRCA1 and BRCA2 in an unselected multiethnic cohort of Asian patients with breast cancer and healthy controls from Malaysia (2017) (33)
Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21 (2016) (33)
Synthetic progestins stimulate prostatic binding protein messenger RNAs in the rat ventral prostate (1990) (33)
Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. (2019) (33)
Congenital adrenal hyperplasia caused by a novel homozygous frameshift mutation 273 delta AA in type II 3 beta-hydroxysteroid dehydrogenase gene (HSD3B2) in three male patients of Afghan/Pakistani origin. (1994) (33)
Family Communication Following BRCA1/2 Genetic Testing: A Close Look at the Process (2013) (32)
Keoxifene shows pure antiestrogenic activity in pituitary gonadotrophs (1985) (32)
Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters. (1997) (32)
Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer. (2010) (32)
Genetic linkage mapping of HSD3B1 and HSD3B2 encoding human types I and II 3β-hydroxysteroid dehydrogenase/Δ5-Δ4-isomerase close to D1S514 and the centromeric D1Z5 locus (1995) (32)
Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus (2016) (32)
A Mendelian randomization analysis of circulating lipid traits and breast cancer risk. (2019) (31)
Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study (2012) (31)
Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study (2014) (31)
Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort (2018) (31)
A common ancestor for mammalian 3 beta-hydroxysteroid dehydrogenase and plant dihydroflavonol reductase. (1990) (31)
Functional characterization of 84 PALB2 variants of uncertain significance (2019) (30)
Identification and characterization of the G15D mutation found in a male patient with 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) deficiency: alteration of the putative NAD-binding domain of type II 3 beta-HSD. (1995) (30)
Synthesis and antiestrogenic activity of diaryl thioether derivatives. (1994) (30)
Dinucleotide repeat polymorphisms in the HSD3B2 gene. (1994) (29)
Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers (2014) (29)
Modulation by sex steroids and [D-Trp6, Des-Gly-NH2(10)]luteinizing hormone (LH)-releasing hormone ethylamide of alpha-subunit and LH beta messenger ribonucleic acid levels in the rat anterior pituitary gland. (1988) (29)
Effect of luteinizing hormone releasing hormone (LHRH) and [D-Trp6, DES-GLy-NH210] LHRH ethylamide on α-subunit and LHβ messenger ribonucleic acid levels in rat anterior pituitary cells in culture (1988) (29)
Atrial natriuretic factor-induced cGMP accumulation in rat anterior pituitary cells in culture is not coupled to hormonal secretion (1986) (29)
Expression of 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase (3β-HSD) and 17B-hydroxysteroid dehydrogenase (17β-HSD) in adipose tissue (1991) (29)
Functional characterization of the novel L108W and P186L mutations detected in the type II 3β-hydroxysteroid dehydrogenase gene of a male pseudohermaphrodite with congenital adrenal hyperplasia (1994) (29)
Antagonism between estrogens and androgens on GCDFP-15 gene expression in ZR-75-1 cells and correlation between GCDFP-15 and estrogen as well as progesterone receptor expression in human breast cancer. (1989) (29)
On the readiness of physicians for pharmacogenomics testing: an empirical assessment (2017) (29)
Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA) (2009) (28)
The AIB1 Polyglutamine Repeat Does Not Modify Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers (2006) (28)
Induction of 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene transcription in human breast cancer cell lines and in normal mammary epithelial cells by interleukin-4 and interleukin-13. (1999) (28)
Glucocorticoids enhance activation of the human type II 3β-hydroxysteroid dehydrogenase/Δ5–Δ4 isomerase gene (2002) (28)
Rapid restriction fragment analysis for screening four point mutations of the Low‐density lipoprotein receptor gene in French Canadians (1995) (27)
Characterization and modulation of sex steroid metabolizing activity in normal human keratinocytes in primary culture and HaCaT cells (2003) (27)
Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs) (2016) (27)
A network analysis to identify mediators of germline-driven differences in breast cancer prognosis (2020) (27)
Return of Research Results: General Principles and International Perspectives (2011) (27)
Genetically predicted levels of DNA methylation biomarkers and breast cancer risk: data from 228,951 women of European descent. (2019) (27)
Ontogenesis of 3β-Hydroxysteroid DehydrogenaseΔ5-Δ4 Isomerase in the Rat Adrenal as Revealed by Immunocytochemistry and in Situ Hybridization (1991) (27)
Mapping of the HSD17B2 gene encoding type II 17 beta-hydroxysteroid dehydrogenase close to D16S422 on chromosome 16q24.1-q24.2. (1995) (26)
Relative potencies of Flutamide and Casodex: preclinical studies (1996) (26)
Characterization of a novel mutation causing hepatic lipase deficiency among French Canadians Published, JLR Papers in Press, June 1, 2003. DOI 10.1194/jlr.M200479-JLR200 (2003) (26)
Purification, Cloning, Complementary DNA Structure, and Predicted Amino Acid Sequence of Human Estradiol 17β‐Dehydrogenase (1990) (26)
A New Insight Into the Molecular Basis of 3β-Hydroxysteroid Dehydrogenase Deficiency (2000) (26)
Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study (2018) (26)
Fine mapping of low-density lipoprotein receptor gene by genetic linkage on chromosome 19p13.1-p13.3 and study of the founder effect of four French Canadian low-density lipoprotein receptor gene mutations. (1999) (25)
Identification of novel breast cancer susceptibility loci in meta-analyses conducted among Asian and European descendants (2020) (25)
Fine-Scale Mapping of the 4q24 Locus Identifies Two Independent Loci Associated with Breast Cancer Risk (2015) (25)
An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers (2015) (25)
Macrophage Scavenger Receptor 1 999C>T (R293X) Mutation and Risk of Prostate Cancer (2005) (25)
The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers (2009) (25)
Structure-function relationships and molecular genetics of the 3β-hydroxysteroid dehydrogenase gene family (1995) (24)
Interactions between Estrogens, Androgens, Progestins, and Glucocorticoids in ZR‐75‐1 Human Breast Cancer Cells (1990) (24)
High risk genes predisposing to prostate cancer development—do they exist? (2000) (24)
Regulation of 3-ketosteroid reductase messenger ribonucleic acid levels and 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase activity in rat liver by sex steroids and pituitary hormones. (1992) (23)
The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations (2018) (23)
Sequence kernel association test for survival outcomes in the presence of a non-susceptible fraction. (2020) (23)
Multihormonal regulation of dehydroepiandrosterone sulfotransferase messenger ribonucleic acid levels in adult rat liver. (1994) (23)
Pure selective estrogen receptor modulators, new molecules having absolute cell specificity ranging from pure antiestrogenic to complete estrogen-like activities. (2001) (22)
Characterization of two mRNA species encoding human estradiol 17 beta-dehydrogenase and assignment of the gene to chromosome 17. (1989) (22)
Multiple signal transduction pathways mediate interleukin-4-induced 3β-hydroxysteroid dehydrogenase/Δ5–Δ4 isomerase in normal and tumoral target tissues (2001) (22)
A new alternative splice variant of BRCA1 containing an additional in-frame exon. (2005) (22)
Health professionals’ perspectives on breast cancer risk stratification: understanding evaluation of risk versus screening for disease (2019) (22)
A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers (2012) (22)
Genetic linkage mapping of the human steroid 5 alpha-reductase type 2 gene (SRD5A2) close to D2S352 on chromosome region 2p23-->p22. (1996) (22)
FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium (2014) (22)
Partnering in Oncogenetic Research – The INHERIT BRCAs Experience: Opportunities and Challenges (2005) (22)
Localization of peripheral benzodiazepine binding sites and diazepam-binding inhibitor (DBI) mRNA in mammary glands and dimethylbenz(α)antracene (DMBA)-induced mammary tumors in the rat (1991) (22)
Linkage analysis of 26 Canadian breast and breast-ovarian cancer families (1995) (21)
Androgenic 17β-hydroxysteroid dehydrogenase activity of expressed rat type I 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase (1992) (21)
Codon 367 polymorphism of the human type I 3 beta-hydroxysteroid dehydrogenase/isomerase gene (HS5DB3). (1991) (21)
Adrenal C19-5-ene steroids induce full estrogenic responses in rat pituitary gonadotrophs. (1987) (21)
Multiple Signaling Pathways Mediate Interleukin-4-Induced 3β-Hydroxysteroid Dehydrogenase/Δ5-Δ4 Isomerase Type 1 Gene Expression in Human Breast Cancer Cells (2000) (21)
Binding of a member of the NF1 family of transcription factors to two distinct cis-acting elements in the promoter and 5'-flanking region of the human cellular retinol binding protein 1 gene. (1994) (21)
Stimulation of Androgen‐Dependent Gene Expression by the Adrenal Precursors Dehydroepiandrosterone and Androstenedione in the Rat Ventral Prostate (1990) (21)
Correction: BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors (2019) (20)
The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer (2019) (20)
Personalizing Breast Cancer Screening Based on Polygenic Risk and Family History (2020) (20)
Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer. (2018) (20)
Somatostatin prevents the desensitizing action of growth hormone-releasing factor on growth hormone release (1987) (20)
Breast and ovarian cancer screening of non-carriers from BRCA1/2 mutation-positive families: 2-year follow-up of cohorts from France and Quebec (2011) (20)
Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry (2016) (20)
Androgenic 17 beta-hydroxysteroid dehydrogenase activity of expressed rat type I 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase. (1992) (20)
Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3 (2016) (20)
Mapping of the regulatory subunits RIβ and RIIβ of cAMP-Dependent protein kinase genes on human chromosome 7 (1992) (19)
Prospective evaluation of a breast-cancer risk model integrating classical risk factors and polygenic risk in 15 cohorts from six countries. (2021) (19)
Gene–environment interactions involving functional variants: Results from the Breast Cancer Association Consortium (2017) (19)
Localization of the catalytic subunit C gamma of the cAMP-dependent protein kinase gene (PRKACG) to human chromosome region 9q13. (1992) (19)
Structure of two in tandem human 17 beta-hydroxysteroid dehydrogenase genes. (1990) (19)
BRCA1 wild-type allele modifies risk of ovarian cancer in carriers of BRCA1 germ-line mutations. (2003) (18)
["Intracrinology". Autonomy and freedom of peripheral tissues]. (1995) (18)
Molecular cloning, upstream sequence and promoter studies of the human gene for the regulatory subunit RII alpha of cAMP-dependent protein kinase. (1997) (18)
Genetic linkage mapping of the CYP11A1 gene encoding the cholesterol side-chain cleavage P450scc close to the CYP1A1 gene and D15S204 in the chromosome 15q22.33-q23 region. (1998) (18)
Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study (2021) (18)
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. (2016) (18)
Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers. (2005) (18)
Medical Genetic Counseling for Breast Cancer in Primary Care: A Synthesis of Major Determinants of Physicians' Practices in Primary Care Settings (2014) (17)
Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. (2018) (17)
Synthesis and structure–activity relationships of analogs of EM-652 (acolbifene), a pure selective estrogen receptor modulator. Study of nitrogen substitution (2005) (17)
A focus group study on breast cancer risk presentation: one format does not fit all (2012) (17)
Localization and regulation of expression of the FAR-17A gene in the hamster flank organs. (1996) (17)
Women’s Views on Multifactorial Breast Cancer Risk Assessment and Risk-Stratified Screening: A Population-Based Survey from Four Provinces in Canada (2021) (17)
Use of Dietary Supplements Among Women at High Risk of Hereditary Breast and Ovarian Cancer (HBOC) Tested for Cancer Susceptibility (2006) (17)
Breast Cancer Risk Estimation and Personal Insurance: A Qualitative Study Presenting Perspectives from Canadian Patients and Decision Makers (2017) (17)
Life Events may Contribute to Family Communication About Cancer Risk Following BRCA1/2 Testing (2013) (17)
Multiple Factors Controlling ACTH Secretion at the Anterior Pituitary Level (1987) (17)
Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium (2019) (17)
Induction of 3beta-hydroxysteroid dehydrogenase/isomerase type 1 expression by interleukin-4 in human normal prostate epithelial cells, immortalized keratinocytes, colon, and cervix cancer cell lines. (1999) (16)
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2mutation carriers (2012) (16)
Localization of the human gene for the type I cyclic GMP-dependent protein kinase to chromosome 10. (1992) (16)
Opposite effects of estrogen and the progestin R5020 on cell proliferation and GCDFP-15 expression in ZR-75-1 human breast cancer cells (1990) (16)
Transcriptome-wide association study of breast cancer risk by estrogen-receptor status (2020) (16)
The gene for hereditary breast-ovarian cancer, BRCA1, maps distal to EDH17B2 in chromosome region 17q12-q21. (1994) (16)
Mutation analysis and characterization of HSD17B2 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer. (2008) (15)
SNP-SNP interaction analysis of NF-κB signaling pathway on breast cancer survival (2015) (15)
Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers (2019) (15)
A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (2021) (15)
CYP17 and breast cancer: no overall effect, but what about interactions? (2005) (15)
Multiple signaling pathways mediate interleukin-4-induced 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene expression in human breast cancer cells. (2000) (15)
Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus (2016) (14)
Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer. (2015) (14)
Self-reported mammography use following BRCA1/2 genetic testing may be overestimated (2012) (14)
Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. (2014) (14)
No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study (2009) (13)
Analysis of 17β-hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Canadian Families with high risk of breast and ovarian cancer (2009) (13)
Exploring resources for intrafamilial communication of cancer genetic risk: we still need to talk (2013) (13)
The knowledge value-chain of genetic counseling for breast cancer: an empirical assessment of prediction and communication processes (2015) (13)
Structure-function relationships of 3 beta-hydroxysteroid dehydrogenase: contribution made by the molecular genetics of 3 beta-hydroxysteroid dehydrogenase deficiency. (1997) (13)
Envisioning Implementation of a Personalized Approach in Breast Cancer Screening Programs: Stakeholder Perspectives (2019) (13)
Structure of primate and rodent orthologs of the prostate cancer susceptibility gene ELAC2. (2004) (13)
Glucocorticoids enhance activation of the human type II 3beta-hydroxysteroid dehydrogenase/Delta5-Delta4 isomerase gene. (2002) (12)
Characterization of human 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase gene and its expression in mammalian cells. (1992) (12)
Disentangling the determinants of interest and willingness-to-pay for breast cancer susceptibility testing in the general population: a cross-sectional Web-based survey among women of Québec (Canada) (2018) (12)
A response to “Personalised medicine and population health: breast and ovarian cancer” (2019) (12)
Multiple signal transduction pathways mediate interleukin-4-induced 3beta-hydroxysteroid dehydrogenase/Delta5-Delta4 isomerase in normal and tumoral target tissues. (2001) (12)
Organizational challenges to equity in the delivery of services within a new personalized risk-based approach to breast cancer screening (2018) (12)
Re-evaluating genetic variants identified in candidate gene studies of breast cancer risk using data from nearly 280,000 women of Asian and European ancestry (2019) (12)
17α-Hydroxylase/17,20-Lyase Deficiency Due to Novel Compound Heterozygote Mutations: Treatment for Tall Stature in a Female with Male Pseudohermaphroditism and Spontaneous Puberty in her Affected Sister (2005) (12)
The association between weight at birth and breast cancer risk revisited using Mendelian randomisation (2018) (12)
Expression of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase (3 beta-HSD) and 17 beta-hydroxysteroid dehydrogenase (17 beta-HSD) in adipose tissue. (1991) (12)
PALB2 Variants: Protein Domains and Cancer Susceptibility. (2020) (11)
Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers (2010) (11)
Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (11)
Structure, regulation and role of 3 beta-hydroxysteroid dehydrogenase, 17 beta-hydroxysteroid dehydrogenase and aromatase enzymes in the formation of sex steroids in classical and peripheral intracrine tissues. (1994) (11)
Genetic sequence variations and ADPRT haplotype analysis in French Canadian families with high risk of breast cancer (2007) (11)
Genetic linkage mapping of the dehydroepiandrosterone sulfotransferase (STD) gene on the chromosome 19q13.3 region. (1995) (11)
Incidence and predictors of positive and negative effects of BRCA1/2 genetic testing on familial relationships: a 3-year follow-up study (2011) (11)
Identification and characterization of novel associations in the CASP 8 / ALS 2 CR 12 region on chromosome 2 with breast cancer risk (2014) (11)
Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium (2015) (10)
AURKA F 31 I Polymorphism and Breast Cancer Risk in BRCA 1 and BRCA 2 Mutation Carriers : A Consortium of Investigators of Modifiers of BRCA 1 / 2 Study (2007) (10)
Prospective Evaluation of a Breast Cancer Risk Model Integrating Classical Risk Factors and Polygenic Risk in 15 Cohorts from Six Countries (2019) (10)
Rapid modulation of ovarian 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase gene expression by prolactin and human chorionic gonadotropin in the hypophysectomized rat. (1994) (10)
The predictive ability of the 313 variant–based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant (2021) (10)
Effectiveness of Risk-Reducing Salpingo-Oophorectomy in Preventing Ovarian Cancer in a High-Risk French Canadian Population (2012) (10)
Transcriptional signature of lymphoblastoid cell lines of BRCA1, BRCA2 and non-BRCA1/2 high risk breast cancer families (2017) (9)
Variations of pre‐proNPY mRNA in the arcuate nucleus during the rat estrous cycle (1992) (9)
Formation and degradation of dihydrotestosterone by recombinant members of the rat 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase family (1994) (9)
Potent Antagonism between Estrogens and Androgens on GCDFP‐15 Expression and Cell Growth in the ZR‐75‐1 Human Breast Cancer Cells a (1990) (9)
Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores (2021) (9)
Effect of the Women's Health Initiative Study Publication on Hormone Replacement Therapy Use among Women Who Have Undergone BRCA1/2 Testing (2007) (9)
Evaluation of associations between genetically predicted circulating protein biomarkers and breast cancer risk (2020) (9)
Changes in health-related behaviours following BRCA 1/2 genetic testing: the case of hormone replacement therapy. (2004) (9)
Opposite effects of prolactin and corticosterone on the expression and activity of 3β-hydroxysteroid dehydrogenase/δ5-δ4 isomerase in rat skin (1994) (9)
Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers (2016) (9)
Localization of Peptide Gene Expression by in Situ Hybridization at Electron Microscopic Level (1989) (9)
Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes (2019) (9)
PHIP - a novel candidate breast cancer susceptibility locus on 6q14.1 (2017) (9)
Characteristics of the desensitization of growth hormone and cyclic AMP responses to growth hormone-releasing factor and prostaglandin E2 in rat anterior pituitary cells in culture (1986) (9)
Estimated potency of casodex: A problematic design [1] (multiple letters) (1997) (8)
Increased Use of BRCA Mutation Test in Unaffected Women Over the Period 2004-2014 in the U.S.: Further Evidence of the "Angelina Jolie Effect"? (2017) (8)
Clinical follow-up and breast and ovarian cancer screening of true BRCA1/2 noncarriers: a qualitative investigation (2015) (8)
Functional analysis of promoter variants in KU70 and their role in cancer susceptibility (2012) (8)
Variations of pre-prosomatostatin MRNA levels in the hypothalamic periventricular nucleus during the rat estrous cycle (1991) (8)
Localization of BRCA1 Gene Expression in Adult Cynomolgus Monkey Tissues (1997) (8)
Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1 updates to tumour pathology and cancer incidence (2022) (8)
Ontogeny and subcellular localization of 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) in the human and rat adrenal, ovary and testis. (1992) (7)
Polygenic risk scores for prediction of breast cancer risk in Asian populations (2021) (7)
Systematic mixed-methods reviews are not ready to be assessed with the available tools. (2011) (7)
Do women change their breast cancer mammogram screening behaviour after BRCA1/2 testing? (2016) (7)
Characterization of HSD17B1 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer (2008) (7)
Open science precision medicine in Canada: Points to consider (2019) (7)
Influence of the family cluster effect on psychosocial variables in families undergoing BRCA1/2 genetic testing for cancer susceptibility (2012) (7)
Assignment of the gene encoding the catalytic subunit Cβ of CAMP-dependent protein kinase to the p36 band on chromosome (1992) (7)
Estimated potency of Casodex: a problematic design. (1997) (7)
Characterization of macaque 3 beta-hydroxy-5-ene steroid dehydrogenase/delta 5-delta 4 isomerase: structure and expression in steroidogenic and peripheral tissues in primate. (1991) (6)
Toward a Population-Based Breast Cancer Risk Stratification Approach? The Needs and Concerns of Healthcare Providers (2021) (6)
Prospective validation of the BOADICEA multifactorial breast cancer risk prediction model in a large prospective cohort study (2022) (6)
Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element (2021) (6)
Common breast cancer risk loci predispose to distinct tumor subtypes (2019) (6)
Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation (2018) (6)
Regulation of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase expression and activity in the hypophysectomized rat ovary: interactions between the stimulatory effect of human chorionic gonadotropin and the luteolytic effect of prolactin. (1990) (6)
Common variants in breast cancer risk loci predispose to distinct tumor subtypes (2022) (6)
Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers (2012) (6)
The AIB 1 Polyglutamine Repeat Does Not Modify Breast Cancer Risk in BRCA 1 and BRCA 2 Mutation Carriers (2006) (6)
Publisher Correction: Personalized early detection and prevention of breast cancer: ENVISION consensus statement (2020) (6)
No Evidence of BRCA 1 / 2 Genomic Rearrangements in High-Risk French-Canadian Breast / Ovarian Cancer Families (2009) (5)
ABRAXAS (FAM175A) and Breast Cancer Susceptibility: No Evidence of Association in the Breast Cancer Family Registry (2016) (5)
Using the Impact of Event Scale to Evaluate Distress in the Context of Genetic Testing for Breast Cancer Susceptibility (2006) (5)
CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers (2021) (5)
Dehydrogenase/{Delta}5-{Delta}4 Isomerase Gene Family Molecular Biology of the 3{beta}-Hydroxysteroid (2005) (5)
Potential of polygenic risk scores for improving population estimates of women’s breast cancer genetic risks (2021) (5)
Analysis of GADD45A sequence variations in French Canadian families with high risk of breast cancer (2008) (5)
Molecular cloning, cDNA structure and predicted amino acid sequence of bovine 3 beta-hydroxy-5-ene steroid dehydrogenase/delta 5-delta 4 isomerase. (1989) (5)
Localization of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase in rat gonads and adrenal glands by immunocytochemistry and in situ hybridization. (1990) (5)
SNP Set Association Testing for Survival Outcomes in the Presence of Intrafamilial Correlation (2015) (5)
Type I Protein C Deficiency in French Canadians: Evidence of a Founder Effect and Association of Specific Protein C Gene Mutations with Plasma Protein C Levels (1998) (5)
Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer (2020) (5)
Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjects (2021) (5)
Large-scale cross-cancer fine-mapping of the 5p15.33 region reveals multiple independent signals (2021) (5)
Functional Analysis of Promoter Variants in Genes Involved in Sex Steroid Action, DNA Repair and Cell Cycle Control (2019) (5)
Mapping of the regulatory subunits RI beta and RII beta of cAMP-dependent protein kinase genes on human chromosome 7. (1992) (5)
Inherited Chromosomally Integrated Human Herpesvirus 6 and Breast Cancer (2016) (5)
Ontogenesis of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase in the rat adrenal as revealed by immunocytochemistry and in situ hybridization. (1991) (5)
Characterization of a novel mutation causing hepatic lipase deﬁciency among French Canadians (2003) (5)
Genetic variation at CYP 3 A is associated with age at menarche and breast cancer risk : a case-control study (2014) (4)
3β-Hydroxysteroid Dehydrogenase Deficiency (2014) (4)
Usefulness of Canadian Public Health Insurance Administrative Databases to Assess Breast and Ovarian Cancer Screening Imaging Technologies for BRCA1/2 Mutation Carriers (2016) (4)
Androgens, DHEA and breast cancer (2005) (4)
Cloning of the human androgen receptor cDNA (1987) (4)
Should Age-Dependent Absolute Risk Thresholds Be Used for Risk Stratification in Risk-Stratified Breast Cancer Screening? (2021) (4)
Common BRCA 2 Variants and Modification of Breast and Ovarian Cancer Risk in BRCA 1 Mutation Carriers (2005) (4)
DSNetwork: An Integrative Approach to Visualize Predictions of Variants’ Deleteriousness (2019) (4)
Publisher Correction: Shared heritability and functional enrichment across six solid cancers (2019) (4)
Molecular Cloning of Rat 3β-HSD: Structure of Two Types of cDNAs and Differential Expression of Corresponding mRNAs in the Ovary (1991) (4)
Mendelian randomisation study of smoking exposure in relation to breast cancer risk (2021) (3)
Erratum: Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer (Journal of Medical Genetics (2007) 44, (107-121)) (2007) (3)
No evidence of excessive cancer screening in female noncarriers from BRCA1/2 mutation-positive families. (2017) (3)
Genomic organization and expression of the mouse Brca2 gene. (2002) (3)
A Collaborative Model to Implement Flexible, Accessible and Efficient Oncogenetic Services for Hereditary Breast and Ovarian Cancer: The C-MOnGene Study (2021) (3)
Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer. (2020) (3)
First World Congress: Hormonal and Genetic Basis of Sexual Differentiation Disorders (2002) (3)
Characterization of the guinea pig 3β-hydroxysteroid dehydrogenase/Δ5–Δ4-isomerase expressed in the adrenal gland and gonads (2005) (3)
Abstract 2598: Predicting breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers using polygenic risk scores (2016) (3)
Stimulatory effect of adrenal steroids on LHRH-induced LH release in rat pituitary cells in culture (1984) (3)
Pure Antagonistic Effect of a New Steroidal Antiestrogen in Rat Anterior Pituitary Cells in Culture and in Mouse Uterus (1990) (3)
Risk-Stratified Approach to Breast Cancer Screening in Canada: Women’s Knowledge of the Legislative Context and Concerns about Discrimination from Genetic and Other Predictive Health Data (2021) (3)
Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer (2020) (3)
Genetic linkage mapping of HSD3B1 and HSD3B2 encoding human types I and II 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase close to D1S514 and the centromeric D1Z5 locus. (1995) (3)
Opposite effects of prolactin and corticosterone on the expression and activity of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase in rat skin. (1994) (3)
Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk (2020) (3)
The CYP17A1 −34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers (2011) (3)
Third- and Fourth-Generation SERMs (2002) (3)
rs2735383, located at a microRNA binding site in the 3’UTR of NBS1, is not associated with breast cancer risk (2016) (2)
Two truncating variants in FANCC and breast cancer risk (2019) (2)
Effect of luteinizing hormone releasing hormone (LHRH) and [D-Trp6, des-Gly-NH2(10)]LHRH ethylamide on alpha-subunit and LH beta messenger ribonucleic acid levels in rat anterior pituitary cells in culture. (1988) (2)
EM-652 (SCH57068), a pure SERM in the mammary gland and endometrium (2001) (2)
A Genome-Wide Gene-Based Gene–Environment Interaction Study of Breast Cancer in More than 90,000 Women (2022) (2)
VEXOR: an integrative environment for prioritization of functional variants in fine‐mapping analysis (2017) (2)
Males With 17β-Hydroxysteroid Dehydrogenase Deficiency (2003) (2)
Women’s perceptions of PERSPECTIVE: a breast cancer risk stratification e-platform (2022) (2)
Genetic testing, physicians and the law: will the tortoise ever catch up with the hare? (2010) (2)
Detection of frequent BglII polymorphism by polymerase chain reaction and TaqI restriction fragment length polymorphism for 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase at the human HSDβ3 locus (1p11–p13) (1991) (2)
Functional characterization of the novel L108W and P186L mutations detected in the type II 3 beta-hydroxysteroid dehydrogenase gene of a male pseudohermaphrodite with congenital adrenal hyperplasia. (1994) (2)
Structure and Control of Expression of the 3βHSD and 17βHSD Genes in Classical Steroidogenic and Peripheral Intracrine Tissues (1993) (2)
26 Blockage of the potent estrogenic activity of 5-androstene-3 8, 17 β-diol (Δ5-diol) and dehydroepiandrosterone (DHEA) by the antiestrogen LY-156758 in rat anterior pituitary cells in culture (1985) (2)
DHEA, The Precursor of Androgens and Estrogens in Peripheral Tissues in the Human: Intracrinology (2000) (2)
Body mass index and the association between low-density lipoprotein cholesterol as predicted by HMGCR genetic variants and breast cancer risk. (2019) (2)
Physical activity, sedentary time and breast cancer risk: a Mendelian randomisation study (2022) (2)
BRCA 1 Wild-Type Allele Modifies Risk of Ovarian Cancer in Carriers of BRCA 1 GermLine Mutations 1 (2003) (2)
Genome- and transcriptome-wide association studies of 386,000 Asian and European-ancestry women provide new insights into breast cancer genetics. (2022) (2)
Molecular Genetics, Structure-Function Relationships, and Tissue-Specific Expression and Regulation of the 3βHSD Gene Family (1994) (2)
Characterization of the guinea pig 3beta-hydroxysteroid dehydrogenase/Delta5-Delta4-isomerase expressed in the adrenal gland and gonads. (2005) (2)
Detection of frequent BglII polymorphism by polymerase chain reaction and TaqI restriction fragment length polymorphism for 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase at the human HSD beta 3 locus (1p11-p13). (1991) (2)
Combination therapy in stage C and D prostatic cancer: rationale and five-year clinical experience (2004) (2)
Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women (2016) (1)
Structure-Function Relationships of Multiple Rat Members of the 3β-Hydroxysteroid Dehydrogenase Family (1993) (1)
Survey of primary care physicians’ views about breast and ovarian cancer screening for true BRCA1/2 non-carriers (2019) (1)
Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study (2014) (1)
Identification of novel breast cancer susceptibility loci in meta-analyses conducted among Asian and European descendants (2020) (1)
Ethical challenges and innovations in the dissemination of genomic data: the experience of the PERSPECTIVE project (2015) (1)
[From the gene to the clinic: prostate cancer death can now be an exception?]. (2003) (1)
A network analysis to identify mediators of germline-driven differences in breast cancer prognosis (2020) (1)
Unoccupied androgen receptors are biologically active in pituitary gonadotrophs (1984) (1)
VEXOR: an integrative environment for prioritization of functional variants in fine-mapping analysis. (2017) (1)
Induction of 3 b -Hydroxysteroid Dehydrogenase/ Isomerase Type 1 Expression by Interleukin-4 in Human Normal Prostate Epithelial Cells, Immortalized Keratinocytes, Colon, and Cervix Cancer Cell Lines* (1999) (1)
Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium (2015) (1)
Identifying 31 novel breast cancer susceptibility loci using data from genome-wide association studies conducted in Asian and European women (2019) (1)
Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers (2020) (1)
HRT use among women tested for BRCA1/2 mutations following publication of the women's health initiative study results. (2005) (1)
Erratum: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: An international prospective cohort of BRCA1 and BRCA2 mutation carriers (Breast Cancer Res (2020) 22 (8) DOI: 10.1186/s13058-020-1247-4) (2020) (1)
Influence of the Duration of Androgen Deprivation on the Sensitivity of the Rat Ventral Prostate to Dehydroepiandrosterone and Androstenedione (1990) (1)
Rare germline copy number variants (CNVs) and breast cancer risk (2022) (1)
Formation and degradation of dihydrotestosterone by recombinant members of the rat 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase family. (1994) (1)
Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers (2022) (1)
Polygenic Risk Modelling for Prediction of Epithelial Ovarian Cancer Risk (2020) (1)
COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration (2013) (1)
Lessons learned and challenges posed in cancer genetics (2013) (1)
Genetic predisposition to ductal carcinoma in situ of the breast (2016) (1)
Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in $\small \textit{BRCA1}$ and $\small \textit{BRCA2}$ Mutation Carriers (2016) (1)
Isolation and Sequence of the Human Glucocorticoid Receptor Gene Promoter. Cloning of the Human Androgen Receptor cDNA (1988) (1)
Genomic organization and expression of the mouse Brca2 gene (2002) (1)
Genome-wide association study of germline variants and breast cancer-speci fi c mortality (2019) (1)
Prediction of breast cancer risk based on common genetic variants in women of East Asian ancestry (2016) (1)
Selected abstracts submitted to the Third International Symposium on Hereditary Breast and Ovarian Cancer (2009) (1)
Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers (2020) (1)
Analysis of multivariate failure times in the presence of selection bias with application to breast cancer (2015) (1)
University of Groningen Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA 1 and BRCA 2 Mutation Carriers (2017) (1)
Uncovering the Contribution of Moderate-Penetrance Susceptibility Genes to Breast Cancer by Whole-Exome Sequencing and Targeted Enrichment Sequencing of Candidate Genes in Women of European Ancestry (2022) (1)
Identiﬁcation of four novel susceptibility loci for oestrogen receptor negative breast cancer (2016) (1)
Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (1)
Antiestrogenic activity of LY156758 in adenohypophysial cells in culture (1984) (0)
Fine-mapping identifies two additional susceptibility 9q31.2. (2015) (0)
a novel candidate breast cancer susceptibility locus on (2017) (0)
Authors' response: associations of obesity and circulating insulin and glucose with breast cancer risk. (2019) (0)
Identification and characterisation of novel associations in the CASP 8 / ALS 2 CR 12 region 1 on chromosome 2 with breast cancer risk 2 3 (2014) (0)
TITLE : Incorporating Truncating Variants in PALB 2 , CHEK 2 and ATM into the BOADICEA Breast Cancer Risk Model SHORT TITLE : Rare Variants in the BOADICEA Breast Cancer Risk Model Authorship (2016) (0)
Using Real-World Data to Determine Health System Costs of Ontario Women Screened for Breast Cancer (2022) (0)
A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer (2018) (0)
rs 2735383 , located at a microRNA binding site in the 3 ’ UTR of NBS 1 , is not associated with breast cancer risk (2016) (0)
BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors (2019) (0)
Abstract 962: Validation of breast cancer risk model incorporating classical risk factors and polygenic risk scores in 14 prospective cohort studies in 6 countries (2019) (0)
Erratum: Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers (Breast cancer research : BCR (2020) 22 1 (8)) (2020) (0)
Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers (2014) (0)
An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers (2015) (0)
Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjects (2021) (0)
Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry (2016) (0)
BRCA1 Gene Expression in Reproductive and Endocrine Tissues in Adult Cynomolgus Monkey (1998) (0)
Abstract 2258: Genome-wide association studies of breast cancer prognosis (2017) (0)
CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers (2021) (0)
Variations in Rates: why we need clinical management recommendations (2007) (0)
Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (2021) (0)
Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers (2020) (0)
Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers (2020) (0)
Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses (2020) (0)
Detection of a novel mutation Y468X in exon 10 of the low-density lipoprotein receptor gene causing heterozygous familial hypercholesterolemia among French Canadians (1994) (0)
Gynecologic Cancer Risk and Genetics: Informing an Ideal Model of Gynecologic Cancer Prevention (2022) (0)
BRCA2 susceptibility gene breast cancer linked to chromosome 13. (1996) (0)
The association between low-density lipoprotein cholesterol predicted by HMGCR genetic variants and breast cancer risk may be mediated by body mass index (2018) (0)
Do women change their breast cancer mammogram screening behaviour after BRCA1/2 testing? (2016) (0)
Mutation analysis oftheBRCA1genein23 families withcases ofcancer ofthebreast, ovary, andmultiple other sites (1996) (0)
Genome-wide association study of germline variants and breast cancer-speci ﬁ c mortality (2019) (0)
Mutations in the 17q-linked breast and ovariecancerprædisponeringen (1995) (0)
OP-JNCI200131 434..442 (2021) (0)
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2. (2023) (0)
Structure-Function Relationships of Multiple Rat Members of (1993) (0)
Combination Therapy with the Antiandrogen Flutamide and the LHRH Agonist [D-Trp 6 , des-Gly-NH 2 10 ]LHRH Ethylamide in Prostate Cancer: Rationale and 5-Year Clinical Experience (1988) (0)
q 31 . 2 and in ZNF 365 are associated with breast cancer risk for BRCA 1 and / or BRCA 2 mutation carriers (2012) (0)
Gene de predisposition au cancer du sein lie au chromosome 13 (1996) (0)
In vivo mutations and polymorphisms in the 17.alpha.-coupled breast and ovarian cancer susceptibility genes (1997) (0)
Mutations associated with the 17q ovarian and breast sensitivity gens (1995) (0)
Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry (2023) (0)
ociation of the Variants CASP 8 D 302 H and CASP 10 0 I with Breast and Ovarian Cancer Risk in B & P A 1 and BRCA 2 Mutation Carriers (2010) (0)
Mutations in the gene for susceptibility to breast and ovarian cancer linked to 17q (1995) (0)
Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes (2020) (0)
THE HETEROGENEITY OF 3β-HYDROXYSTEROID DEHYDRO GENASE (3β-HSD) DEFICIENCY - REPORT OF 4 CASES (1993) (0)
Abstract 2783: Common functional mechanisms underlying pleiotropy at the 19p13.1 breast and ovarian cancer cusceptibility locus (2015) (0)
Mutations of the 17q associated ovarian and breast cancer susceptibility gene (1995) (0)
Conversion of precursor adrenal steroids into potent androgens in peripheral tissues (1989) (0)
Shared heritability and functional enrichment across six solid cancers (2019) (0)
Mutations of the gene related to chromosome 17q, susceptibility to cancer of breast and ovary. (1995) (0)
Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer (2019) (0)
Abstract 3222: Evaluation of associations between circulating proteins and breast cancer risk using genetic variants (2018) (0)
AD51B in Familial Breast Cancer (2016) (0)
Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
Rare copy number variants (CNVs) and breast cancer risk (2021) (0)
Mutations associated with the 17q ovarian and breast cancer susceptibility gene (1995) (0)
Genome-wide association study of germline variants and breast cancer-specific mortality (2019) (0)
Genetic variation in the immunosuppression pathway genes and breast cancer: a pooled analysis of 42,510 cases and 40,577 controls from the Breast (2015) (0)
[Structure and expression of the genes encoding the enzymes for ovarian and peripheral steroidogenesis]. (1992) (0)
Functional characterization of 84 PALB2 variants of uncertain significance (2019) (0)
No evidence of recurent BRCA1/2 genomic rearrangement in high risk French-Canadian breast/ovarian cancer families (2003) (0)
Association of breast cancer risk in BRCA 1 and BRCA 2 mutation carriers with genetic variants showing differential allelic expression (2016) (0)
The Passing of Dr. Fernand Labrie (1937–2019): The legacy of excellence in science (2019) (0)
Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
INHERIT BRCAs Partnering in Oncogenetic Research – The INHERIT BRCAs Experience: Opportunities and Challenges (2005) (0)
Androgens in post-menopause (1991) (0)
Abstract 1309: Association between insulin resistance and breast cancer risk: A Mendelian randomization analysis of data from 228,000 women of European descent (2017) (0)
An Improved Polygenic Risk Score for Risk Prediction in Breast Cancer (2017) (0)
Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
Inhibition of Cell Cycle Kinetics and Proliferation by the Androgen 5a-Dihydrotestosterone and Antiestrogen A^,/i-Butyl-A^-methyl-ll-Undecanamide in Human Breast Cancer ZR-75-1 Cells1 (2006) (0)
Mutations linked to chromosome 17q, susceptibility breast cancer and ovarian gene. (1995) (0)
University of Groningen DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers Osorio, (2014) (0)
Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus (2016) (0)
The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer (2019) (0)
Correction: BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors (2019) (0)
Chromosome 13 associated Brustkrebsempfindlichkeitsgen BRCA2 (1996) (0)
Effect of Luteinizing Hormone Releasing Hormone (LHRH) and [D-Trp, Des-Gly-NH2 (2008) (0)
HRCA-I gene mutation is commonly identified among women with early-onset breast cancer and is particularly common in Jewish women (1996) (0)
Common variants in breast cancer risk loci predispose to distinct tumor subtypes (2022) (0)
1.P.233 Molecular evidence of founder effect for four mutations in the low-density lipoprotein receptor gene in French Canadians with familial hypercholesterolemia (1997) (0)
Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
Tamoxifen and risk of contralateral breast cancer for \textitBRCA1 and \textitBRCA2 mutation carriers (2013) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Jacques Simard,?

Jacques Simard, is affiliated with the following schools:

Jacques Simard,'s Academic­Influence.com Rankings

Why Is Jacques Simard, Influential?

Jacques Simard,'s Published Works

Published Works

What Schools Are Affiliated With Jacques Simard,?

Jacques Simard,'s AcademicInfluence.com Rankings